Related Experiment Video
Updated: May 20, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Dermatomyofibromas harbor PDGFRB mutations - another tyrosine kinase-driven neoplasm
Uta Flucke1,2, Laura S Hiemcke-Jiwa3,4, Joost M van Gorp5
1Department of Pathology, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. uta.flucke@radboudumc.nl.
Abstract:
Platelet-derived growth factor receptor beta (PDGFRB) is one of the numerous members of the receptor tyrosine kinase protein family. When altered, it is known to be the driver mutation in different mesenchymal neoplasms, such as pericytic tumors, inflammatory myofibroblastic tumor, and sarcomas with myogenic differentiation. We investigated seven dermatomyofibromas for the presence of a PDGFRB mutation. Patients were 6 females and 1 male. Ages ranged from 2 to 59 years. Neoplasms were located in the shoulder (2), neck (2), upper arm (1), knee (1), and calf (1). Clinically, they appeared as ill-defined plaques. Complete excision was performed in four cases. In three cases, only a biopsy was taken. Histomorphologically, these dermal ill-defined tumors consisted of fascicles of slender myofibroblastic cells oriented often parallel to the epidermis. Their nuclei were monomorphic and elongated, and the cytoplasm was inconspicuous. Involvement of the superficial subcutis was seen in four cases. Immunohistochemically, neoplasms expressed SMA (5/7), focally desmin (1/5), and CD34 (4/6), while S100 was lacking (0/7). By DNA or RNA sequencing, PDGFRB activating mutations were identified in 6/7 tumors. Four neoplasms harbored a mutation in exon 12 encoding for the juxtamembrane domain and 2 neoplasms in exon 14 encoding for the tyrosine kinase domain. Sequencing analyses results highlight that these benign skin tumors belong to the broad spectrum of tyrosine kinase-driven neoplasms.
Insights
Activating mutations in Platelet-Derived Growth Factor Receptor Beta (PDGFRB) drive dermatomyofibromas, a type of benign skin tumor. These PDGFRB mutations were identified in most investigated cases, linking them to tyrosine kinase-driven neoplasms.
Area of Science:
- Oncology
- Dermatology
- Genetics
Background:
- Platelet-Derived Growth Factor Receptor Beta (PDGFRB) is a receptor tyrosine kinase implicated in mesenchymal neoplasms.
- Alterations in PDGFRB are known drivers in various tumors, including pericytic tumors and sarcomas.
Purpose of the Study:
- To investigate the presence and type of PDGFRB mutations in dermatomyofibromas.
- To determine if dermatomyofibromas are associated with tyrosine kinase-driven alterations.
Main Methods:
- Seven dermatomyofibroma cases were analyzed.
- Histomorphological and immunohistochemical analyses were performed.
- DNA or RNA sequencing was used to identify PDGFRB mutations.
Main Results:
- PDGFRB activating mutations were found in 6 out of 7 dermatomyofibromas.
- Mutations were located in exon 12 (juxtamembrane domain) or exon 14 (tyrosine kinase domain).
- Neoplasms showed characteristic myofibroblastic morphology and expressed SMA and CD34.
Conclusions:
- Dermatomyofibromas harbor PDGFRB activating mutations.
- These findings classify dermatomyofibromas within the spectrum of tyrosine kinase-driven neoplasms.
- The study highlights the importance of molecular profiling in understanding benign skin tumors.
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation

